Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase III Trial
Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase III Trial Inside Precision Medicine
Онкология
🎗️Лента новостей
Онкология
‘Practice-changing’ new lung cancer immunotherapy improves survival
‘Practice-changing’ new lung cancer immunotherapy improves survival NBC News
Онкология
QL1706 at ESMO 2026: Dual PD-1/CTLA-4 Immunotherapy Improves Overall Survival in Advanced Cervical Cancer
QL1706 at ESMO 2026: Dual PD-1/CTLA-4 Immunotherapy Improves Overall Survival in Advanced Cervical Cancer Oncodaily
🎗️
Онкология
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma HMP Global Learning Network
🎗️
Онкология
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma HMP Global Learning Network
Онкология
Опухоль удалили, но опасность осталась: персональная вакцина помогает снизить риск рецидива
Опухоль удалили, но опасность осталась: персональная вакцина помогает снизить риск рецидива Правда.Ру
Онкология
BEATcc at ESMO 2026: Atezolizumab Extends Overall Survival to 31.9 Months in Advanced Cervical Cancer
BEATcc at ESMO 2026: Atezolizumab Extends Overall Survival to 31.9 Months in Advanced Cervical Cancer Oncodaily
Онкология
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer UT MD Anderson
Онкология
Temab-A + Bevacizumab at ESMO 2026: Long-Term Phase I Results in Previously Treated Colorectal Cancer
Temab-A + Bevacizumab at ESMO 2026: Long-Term Phase I Results in Previously Treated Colorectal Cancer Oncodaily
Онкология
KEYNOTE-B21 at ESMO 2026: Pembrolizumab Improves Disease-Free Survival in dMMR Endometrial Cancer, While ctDNA Shows Limited Predictive Value
KEYNOTE-B21 at ESMO 2026: Pembrolizumab Improves Disease-Free Survival in dMMR Endometrial Cancer, While ctDNA Shows Limited Predictive Value Oncodaily
Онкология
ESMO26: Halda buy delivers a win for J&J in prostate cancer
ESMO26: Halda buy delivers a win for J&J in prostate cancer pharmaphorum
Онкология
Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration
Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration Yahoo Finance
Онкология
ESMO 2026: Immunotherapy Combination Extends Survival in Advanced Endometrial Cancer | Newswise
ESMO 2026: Immunotherapy Combination Extends Survival in Advanced Endometrial Cancer | Newswise Newswise